GCP
DNLI icon

GSA Capital Partners’s Denali Therapeutics DNLI Stock Holding History

GSA Capital Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-37,404
Closed -$772K – 1584
2023
Q3 		$772K Buy
+37,404
New +$949K 0.07% 537
2022
Q2 		– Sell
-6,940
Closed -$223K – 1480
2022
Q1 		$223K Buy
6,940
+1,106
+19% +$38.1K 0.03% 1109
2021
Q4 		$260K Sell
5,834
-9,058
-61% -$429K 0.03% 1036
2021
Q3 		$751K Buy
+14,892
New +$839K 0.08% 454
2021
Q2 		– Sell
-5,583
Closed -$319K – 1368
2021
Q1 		$319K Buy
+5,583
New +$374K 0.05% 604
2019
Q3 		– Sell
-25,564
Closed -$531K – 1463
2019
Q2 		$531K Buy
25,564
+16,244
+174% +$364K 0.06% 633
2019
Q1 		$216K Buy
+9,320
New +$195K 0.02% 1202

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return